Correction of dyslipidemia with combined use of beta-sitosterol and polyprenyl phosphates in dogs with type 1 diabetes mellitus

This study considers the efficiency of use of a combined drug based on beta-sitosterol and polyprenyl phosphates in dogs with type I diabetes mellitus complicated by hyperlipidemia. It was shown that after 1 month of the therapy, there was a significant decrease of the level of cholesterol, triglycerides and glucose vs. control animals. After 2 months of the therapy, in the control group the level of cholesterol and triglycerides was at the upper limit of the norm, which can lead to an exacerbation of the disease in future.